National Cancer Institute (NCI): Bile Duct Neoplasms trials

The registry lists 27 Bile Duct Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 4 are open to participants now and 13 have results posted.

Phase 1 6Phase 2 21No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)RecruitingNCT05849480Phase 1/2
• PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaRecruitingNCT05286814Phase 2
• Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersRecruitingNCT04645160Phase 1/2
• Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruitingNCT01915225
• Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).TerminatedNCT04566133Phase 2Results posted
• Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)CompletedNCT03111732Phase 2Results posted
• A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedNCT02821754Phase 2Results posted
• Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by SurgeryCompletedNCT02042443Phase 2Results posted
• MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by SurgeryCompletedNCT01425879Phase 2Results posted
• Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary CancersTerminatedNCT01229111Phase 2Results posted
• Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT01093222Phase 2Results posted
• Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By SurgeryCompletedNCT00553332Phase 2Results posted
• Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryTerminatedNCT00478140Phase 2Results posted
• Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsCompletedNCT00356889Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract CancerCompletedNCT00107536Phase 2Results posted
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00101036Phase 2Results posted
• Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or GallbladderTerminatedNCT00085410Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryWithdrawnNCT01859182Phase 2
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT00238212Phase 2
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerCompletedNCT00033462Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• BMS-247550 in Treating Patients With Liver or Gallbladder CancerTerminatedNCT00023946Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1